Berlin, Berlin, Germany
Arndt Rolfs is a Professor at the University of Rostock, Germany, multi-entrepreneur in biotech, eg CEO and co-founder of subrosa OmicsAI, CEO of RCV GmbH, CEO and founder of Arcensus (www.arcensus-diagnostics.com), founder and former CEO of CENTOGENE (www.centogene.com). He received his MD in 1985, and was granted a tenure track professorship for clinical neurology in 1997 at the University of Rostock. In 2008, Arndt was appointed Director of the Albrecht-Kossel-Institute for Neuroregeneration at the University of Rostock. Arndt is a principal investigator of several international multicenter studies in the area of rare diseases, one of the largest and most ethnically diverse studies of Parkinson’s disease, several biomarker studies (e.g. BioGaucher, BioHunter, BioMorquio), and epidemiological studies in neurogenetic aetiologies. Arndt has an extensive track record in medical and scientific publications. “A life-long dedication to our patients” is what drives Arndt every day.
subrosa OmicsAI is a subrosa Health & Capital Group company. At subrosa OmicsAI we are building a new kind of platform: one that combines the power of -omics technologies, real-world data, and AI-driven mathematical models to identify patients earlier, more accurately, and always ethically. Because behind every data point is a patient - and every diagnosis can change a life.
To succeed in the field of rare diseases, innovative companies need a perfectly fitting business model and a carefully aligned set of capabilities in patient access, market access and patient organizations. We develop the strategy and operating model essential for success in this booming market. With more than 30 years of founder experience, we accelerate time to market by developing fit-for-purpose global market models, processes and infrastructure.
#arcensus is the most recent start-up Arndt has founded. www.arcensus-diagnostics.com Arcensus is a digital healthcare and diagnostics company that empowers people to take control of their health. As we believe that good health should not be a matter of luck, but rather a matter of informed and timely action. Therefore, we provide a secure, trusted, and comprehensive medical service based on Whole Genome Sequencing (WGS). We analyse the complete genetic information in human DNA and identify the predispositions as well as reasons for unclear symptoms with the help of cutting-edge technology like artificial intelligence. Our detailed genetic report suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life.
Agyany Pharma is focused on delivering commercially viable therapies for Gaucher disease (GBA1 deficiency) and Sidransky syndrome (GBA1-related Parkinson) - two areas of high unmet need. By leveraging Ambroxol’s unique pharmacological profile (our lead substance) to restore GCase function, we offer a differentiated approach with strong clinical rationale and global scalability.